Cargando…
Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis
Background: The association between the effectiveness of capecitabine and the concomitant administration of gastric acid suppressants remains controversial. We aimed to clarify whether the effectiveness of capecitabine is affected by the co-administration of histamine H(2) receptor antagonists (H(2)...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414027/ https://www.ncbi.nlm.nih.gov/pubmed/36046656 http://dx.doi.org/10.7150/jca.73385 |
_version_ | 1784775894283321344 |
---|---|
author | Yamazaki, Tomoko Uozumi, Ryuji Kawazoe, Hitoshi Kitazume, Yoshiko Iihara, Hirotoshi Fujii, Hironori Takahashi, Masaya Arai, Takahiro Murachi, Yasushi Sato, Yumiko Mikami, Takahiro Hashiguchi, Koji Yoshizawa, Tomoe Takahashi, Katsuyuki Fujita, Yukiyoshi Hosokawa, Yuki Morozumi, Issei Tsuchiya, Masami Yokoyama, Atsushi Hashimoto, Hironobu Furukawa, Tetsuya |
author_facet | Yamazaki, Tomoko Uozumi, Ryuji Kawazoe, Hitoshi Kitazume, Yoshiko Iihara, Hirotoshi Fujii, Hironori Takahashi, Masaya Arai, Takahiro Murachi, Yasushi Sato, Yumiko Mikami, Takahiro Hashiguchi, Koji Yoshizawa, Tomoe Takahashi, Katsuyuki Fujita, Yukiyoshi Hosokawa, Yuki Morozumi, Issei Tsuchiya, Masami Yokoyama, Atsushi Hashimoto, Hironobu Furukawa, Tetsuya |
author_sort | Yamazaki, Tomoko |
collection | PubMed |
description | Background: The association between the effectiveness of capecitabine and the concomitant administration of gastric acid suppressants remains controversial. We aimed to clarify whether the effectiveness of capecitabine is affected by the co-administration of histamine H(2) receptor antagonists (H(2)RAs) in early-stage colorectal cancer (CRC) patients using real-world data. Methods: This multicenter, retrospective, observational study included consecutive patients with stage II-III CRC who received either capecitabine monotherapy or the CapeOX regimen (capecitabine and oxaliplatin) as adjuvant therapy between January 2009 and December 2014 in Japan. Relapse-free survival (RFS) and overall survival were estimated using the Kaplan-Meier method. Additionally, multivariable Cox proportional hazards model, propensity score adjustment, and inverse probability of treatment weighting analyses were performed. Results: In total, 552 patients were included in this study, of which 30 were co-administered H(2)RAs. RFS at five years was 76.7% (95% confidence interval [CI]: 57.2-88.1%) and 79.8% (95% CI: 76.0-83.0%) in the H(2)RA and non-H(2)RA groups, respectively. Multivariable Cox proportional hazards model and propensity score-adjusted analyses showed that the co-administration of H(2)RAs was associated with a poor RFS among those receiving capecitabine monotherapy (hazard ratio [HR], 2.01; 95% CI: 0.86-4.70 and HR, 1.81; 95% CI: 0.77-4.22, respectively). In contrast, these results were inconsistent with the group receiving the CapeOX regimen. Conclusions: The study findings suggest that the co-administration of H(2)RAs may not reduce the effectiveness of capecitabine therapy in patients with early-stage CRC. To confirm this relationship, a prospective study with a pharmacokinetic approach is needed. |
format | Online Article Text |
id | pubmed-9414027 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-94140272022-08-30 Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis Yamazaki, Tomoko Uozumi, Ryuji Kawazoe, Hitoshi Kitazume, Yoshiko Iihara, Hirotoshi Fujii, Hironori Takahashi, Masaya Arai, Takahiro Murachi, Yasushi Sato, Yumiko Mikami, Takahiro Hashiguchi, Koji Yoshizawa, Tomoe Takahashi, Katsuyuki Fujita, Yukiyoshi Hosokawa, Yuki Morozumi, Issei Tsuchiya, Masami Yokoyama, Atsushi Hashimoto, Hironobu Furukawa, Tetsuya J Cancer Research Paper Background: The association between the effectiveness of capecitabine and the concomitant administration of gastric acid suppressants remains controversial. We aimed to clarify whether the effectiveness of capecitabine is affected by the co-administration of histamine H(2) receptor antagonists (H(2)RAs) in early-stage colorectal cancer (CRC) patients using real-world data. Methods: This multicenter, retrospective, observational study included consecutive patients with stage II-III CRC who received either capecitabine monotherapy or the CapeOX regimen (capecitabine and oxaliplatin) as adjuvant therapy between January 2009 and December 2014 in Japan. Relapse-free survival (RFS) and overall survival were estimated using the Kaplan-Meier method. Additionally, multivariable Cox proportional hazards model, propensity score adjustment, and inverse probability of treatment weighting analyses were performed. Results: In total, 552 patients were included in this study, of which 30 were co-administered H(2)RAs. RFS at five years was 76.7% (95% confidence interval [CI]: 57.2-88.1%) and 79.8% (95% CI: 76.0-83.0%) in the H(2)RA and non-H(2)RA groups, respectively. Multivariable Cox proportional hazards model and propensity score-adjusted analyses showed that the co-administration of H(2)RAs was associated with a poor RFS among those receiving capecitabine monotherapy (hazard ratio [HR], 2.01; 95% CI: 0.86-4.70 and HR, 1.81; 95% CI: 0.77-4.22, respectively). In contrast, these results were inconsistent with the group receiving the CapeOX regimen. Conclusions: The study findings suggest that the co-administration of H(2)RAs may not reduce the effectiveness of capecitabine therapy in patients with early-stage CRC. To confirm this relationship, a prospective study with a pharmacokinetic approach is needed. Ivyspring International Publisher 2022-08-08 /pmc/articles/PMC9414027/ /pubmed/36046656 http://dx.doi.org/10.7150/jca.73385 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Yamazaki, Tomoko Uozumi, Ryuji Kawazoe, Hitoshi Kitazume, Yoshiko Iihara, Hirotoshi Fujii, Hironori Takahashi, Masaya Arai, Takahiro Murachi, Yasushi Sato, Yumiko Mikami, Takahiro Hashiguchi, Koji Yoshizawa, Tomoe Takahashi, Katsuyuki Fujita, Yukiyoshi Hosokawa, Yuki Morozumi, Issei Tsuchiya, Masami Yokoyama, Atsushi Hashimoto, Hironobu Furukawa, Tetsuya Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis |
title | Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis |
title_full | Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis |
title_fullStr | Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis |
title_full_unstemmed | Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis |
title_short | Association between the Co-administration of Histamine H(2) Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score Analysis |
title_sort | association between the co-administration of histamine h(2) receptor antagonists and the effectiveness of capecitabine in patients with colorectal cancer: propensity score analysis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414027/ https://www.ncbi.nlm.nih.gov/pubmed/36046656 http://dx.doi.org/10.7150/jca.73385 |
work_keys_str_mv | AT yamazakitomoko associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT uozumiryuji associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT kawazoehitoshi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT kitazumeyoshiko associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT iiharahirotoshi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT fujiihironori associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT takahashimasaya associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT araitakahiro associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT murachiyasushi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT satoyumiko associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT mikamitakahiro associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT hashiguchikoji associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT yoshizawatomoe associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT takahashikatsuyuki associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT fujitayukiyoshi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT hosokawayuki associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT morozumiissei associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT tsuchiyamasami associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT yokoyamaatsushi associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT hashimotohironobu associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis AT furukawatetsuya associationbetweenthecoadministrationofhistamineh2receptorantagonistsandtheeffectivenessofcapecitabineinpatientswithcolorectalcancerpropensityscoreanalysis |